### Table 5: GRADE evidence profile for oral amantadine versus no antiviral therapy

<table>
<thead>
<tr>
<th>Study Event Rates (%)</th>
<th>Relative Effect (95% CI)</th>
<th>Anticipated Absolute Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>With no antiviral treatment</td>
<td>With amantadine</td>
<td></td>
</tr>
<tr>
<td>1,2,3</td>
<td>0.04 (0 to 0.73)</td>
<td>129 deaths per 1000 (from 31 to 129 fewer)</td>
</tr>
<tr>
<td>4,5</td>
<td>OR 0.76 (0.38 to 1.53)</td>
<td>387 pneumonia per 1000 (from 194 fewer to 104 more)</td>
</tr>
</tbody>
</table>

#### Quality Assessment
- **Risk of bias:**
  - Serious
  - No serious inconsistency
  - No serious indirectness
  - Serious
  - Undetected

- **Inconsistency:**
  - Very Low due to risk of bias, imprecision

- **Indirectness:**
  - No serious

- **Imprecision:**
  - Undetected

- **Publication bias:**
  - Undetected

- **Overall quality of evidence:**
  - Very Low

### Summary of Findings

#### Mortality

- 139 (1 study)
- **Risk of bias:** Serious
- **Inconsistency:** No serious
- **Indirectness:** No serious
- **Imprecision:** Undetected
- **Overall quality of evidence:** Very Low due to risk of bias, imprecision
- **Study event rates (%):** 8/62 (12.9%) vs. 0/77 (0%)
- **Relative effect:** OR 0.04 (0 to 0.73)
- **Anticipated absolute effects:** 129 deaths per 1000 (from 31 to 129 fewer)

#### Duration of Hospitalisation

- 78 (1 study)
- **Risk of bias:** Serious
- **Inconsistency:** No serious
- **Indirectness:** No serious
- **Imprecision:** Undetected
- **Overall quality of evidence:** Very Low due to risk of bias, imprecision
- **Study event rates (%):** 27 vs. 51
- **Relative effect:** No comparison
- **Anticipated absolute effects:** The mean duration of hospitalisation was 1.01 fewer days (0.27 to 1.75 fewer)

#### Duration of Signs and Symptoms

- 1508 (3 studies)
- **Risk of bias:** Serious
- **Inconsistency:** No serious
- **Indirectness:** No serious
- **Imprecision:** Undetected
- **Overall quality of evidence:** Very Low due to risk of bias, inconsistency
- **Study event rates (%):** - vs. -
- **Relative effect:** No comparison
- **Anticipated absolute effects:** -

#### Complications - Pneumonia

- 139 (1 study)
- **Risk of bias:** Serious
- **Inconsistency:** No serious
- **Indirectness:** No serious
- **Imprecision:** Undetected
- **Overall quality of evidence:** Very Low due to risk of bias, imprecision
- **Study event rates (%):** 24/62 (38.7%) vs. 25/77 (32.5%)
- **Relative effect:** OR 0.76 (0.38 to 1.53)
- **Anticipated absolute effects:** 387 pneumonia per 1000 (from 194 fewer to 104 more)

#### Minor Adverse Events

- 832 (3 studies)
- **Risk of bias:** Serious
- **Inconsistency:** No serious
- **Indirectness:** No serious
- **Imprecision:** Undetected
- **Overall quality of evidence:** Very Low due to risk of bias
- **Study event rates (%):** 6/832 (0.7%)
- **Relative effect:** No comparison
- **Anticipated absolute effects:** -

---

1. Studies not adjusted for potential confounding factors.
2. Few events and participants.
3. Although we did not downgrade, publication bias cannot be excluded.
Studies did not have comparison groups.

High heterogeneity among studies.

The mean time to alleviation of symptoms for people who had amantadine was 64 hours (63 to 65 hours). There is no comparison group.